newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indica